FR23C1039I1 - Derives de piperidinone carboxamide azaindane en tant qu'antagonistes du recepteur cgrp - Google Patents

Derives de piperidinone carboxamide azaindane en tant qu'antagonistes du recepteur cgrp

Info

Publication number
FR23C1039I1
FR23C1039I1 FR23C1039C FR23C1039C FR23C1039I1 FR 23C1039 I1 FR23C1039 I1 FR 23C1039I1 FR 23C1039 C FR23C1039 C FR 23C1039C FR 23C1039 C FR23C1039 C FR 23C1039C FR 23C1039 I1 FR23C1039 I1 FR 23C1039I1
Authority
FR
France
Prior art keywords
receptor antagonists
cgrp receptor
derivatives
piperidinone carboxamide
carboxamide azaindane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1039C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of FR23C1039I1 publication Critical patent/FR23C1039I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR23C1039C 2010-11-12 2023-10-31 Derives de piperidinone carboxamide azaindane en tant qu'antagonistes du recepteur cgrp Active FR23C1039I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41307710P 2010-11-12 2010-11-12
US201061425034P 2010-12-20 2010-12-20
PCT/US2011/060081 WO2012064910A1 (en) 2010-11-12 2011-11-10 Piperidinone carboxamide azaindane cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
FR23C1039I1 true FR23C1039I1 (fr) 2023-12-08

Family

ID=45034191

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1039C Active FR23C1039I1 (fr) 2010-11-12 2023-10-31 Derives de piperidinone carboxamide azaindane en tant qu'antagonistes du recepteur cgrp

Country Status (42)

Country Link
US (8) US8481556B2 (hu)
EP (2) EP2638042B1 (hu)
JP (1) JP5642883B2 (hu)
KR (1) KR101537877B1 (hu)
CN (1) CN103328478B (hu)
AR (1) AR083831A1 (hu)
AU (1) AU2011326454B2 (hu)
BR (1) BR112013011448B8 (hu)
CA (1) CA2817100C (hu)
CL (1) CL2013001289A1 (hu)
CO (1) CO6801723A2 (hu)
CR (1) CR20130214A (hu)
CY (2) CY1118362T1 (hu)
DK (2) DK2638042T3 (hu)
DO (1) DOP2013000103A (hu)
EA (1) EA022850B1 (hu)
EC (1) ECSP13012676A (hu)
ES (2) ES2525021T3 (hu)
FI (1) FIC20230034I1 (hu)
FR (1) FR23C1039I1 (hu)
GT (1) GT201300122A (hu)
HK (1) HK1200163A1 (hu)
HR (2) HRP20141108T1 (hu)
HU (2) HUE031010T2 (hu)
IL (1) IL225978A (hu)
LT (1) LT2821407T (hu)
MA (1) MA34650B1 (hu)
ME (2) ME02552B (hu)
MX (1) MX2013005246A (hu)
MY (1) MY165113A (hu)
NI (1) NI201300043A (hu)
NL (1) NL301248I2 (hu)
NO (1) NO2023040I1 (hu)
NZ (1) NZ610468A (hu)
PE (1) PE20140240A1 (hu)
PL (2) PL2638042T3 (hu)
PT (2) PT2638042E (hu)
RS (2) RS55416B1 (hu)
SG (2) SG190137A1 (hu)
SI (2) SI2821407T1 (hu)
TW (3) TWI487706B (hu)
WO (1) WO2012064910A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI487706B (zh) * 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2685826B1 (en) 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9487523B2 (en) * 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
US20160220552A1 (en) * 2013-09-16 2016-08-04 Merck Sharp & Dohme Corp. Formulations for cgrp receptor antagonists
EP3102564A4 (en) * 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US20190374520A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
CN110787163B (zh) * 2019-12-05 2020-06-02 河北医科大学第二医院 一种用于神经保护和促进神经再生的药物组合物及其制剂
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
MX2023007575A (es) 2020-12-22 2023-09-21 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3212151A1 (en) 2021-03-02 2022-09-09 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023119327A1 (en) * 2021-12-20 2023-06-29 Msn Laboratories Private Limited, R&D Center Process for the preparation of a pure amorphous form of ubrogepant
CN117003762A (zh) * 2022-04-29 2023-11-07 熙源安健医药（上海）有限公司 哌啶甲酰胺氮杂茚满类衍生物及其制备方法和用途
WO2024081718A1 (en) 2022-10-11 2024-04-18 Allergan Pharmaceuticals International Limited Cgrp receptor antagonist for the treatment of migraine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US7205293B2 (en) 2003-03-14 2007-04-17 Merck & Co., Inc. Benodiazepine spirohydantoin CGRP receptor antagonists
AU2004222378B2 (en) 2003-03-14 2008-08-14 Merck Sharp & Dohme Corp. Carboxamide spirohydantoin CGRP receptor antagonists
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
EP1797073B1 (en) * 2004-09-13 2010-04-14 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam cgrp receptor antagonists
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US7994325B2 (en) * 2005-03-14 2011-08-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
KR20090018107A (ko) * 2006-05-09 2009-02-19 머크 앤드 캄파니 인코포레이티드 치환된 스피로사이클릭 ｃｇｒｐ 수용체 길항제
US8993588B2 (en) 2007-06-05 2015-03-31 Merck Sharp & Dohme Corp. Carboxamide heterocyclic CGRP receptor antagonists
EP2225237A2 (de) * 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organische verbindungen
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8765763B2 (en) * 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
CA2816974A1 (en) * 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane cgrp receptor antagonists
TWI487706B (zh) * 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2654421B1 (en) * 2010-12-22 2016-10-19 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide as cgrp receptor antagonists
US9067941B2 (en) * 2010-12-22 2015-06-30 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide CGRP receptor antagonists
EP2685826B1 (en) * 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9109209B2 (en) * 2011-09-08 2015-08-18 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
US9487523B2 (en) * 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
EP2825536B1 (en) * 2012-03-14 2020-06-17 Merck Sharp & Dohme Corp. Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
US9227973B2 (en) * 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Pyridine CGRP receptor antagonists
EP2846799B1 (en) * 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
US9174989B2 (en) * 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
EP2846798B1 (en) * 2012-05-09 2018-04-04 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
US20160220552A1 (en) * 2013-09-16 2016-08-04 Merck Sharp & Dohme Corp. Formulations for cgrp receptor antagonists
EP3102564A4 (en) * 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
CN106456662A (zh) * 2014-02-24 2017-02-22 奥利金制药公司 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
US20180092899A1 (en) * 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound

Also Published As

Publication number Publication date
HRP20141108T1 (hr) 2015-01-16
PL2638042T3 (pl) 2015-03-31
CR20130214A (es) 2013-06-28
TW201520214A (zh) 2015-06-01
MX2013005246A (es) 2013-05-28
HRP20161641T1 (hr) 2017-01-13
DOP2013000103A (es) 2013-10-15
TW201520213A (zh) 2015-06-01
TWI501968B (zh) 2015-10-01
HUS2300037I1 (hu) 2023-11-28
PT2821407T (pt) 2016-12-06
LT2821407T (lt) 2016-12-12
AU2011326454B2 (en) 2015-05-21
KR101537877B1 (ko) 2015-07-17
MA34650B1 (fr) 2013-11-02
EA022850B1 (ru) 2016-03-31
NL301248I2 (nl) 2023-11-20
ME01922B (me) 2015-05-20
CL2013001289A1 (es) 2013-08-09
SI2821407T1 (sl) 2016-12-30
CA2817100C (en) 2015-09-29
AR083831A1 (es) 2013-03-27
CY1118362T1 (el) 2017-06-28
JP5642883B2 (ja) 2014-12-17
RS55416B1 (sr) 2017-04-28
EP2821407B1 (en) 2016-09-21
US10272077B2 (en) 2019-04-30
TWI487706B (zh) 2015-06-11
BR112013011448B8 (pt) 2022-03-29
HK1200163A1 (zh) 2015-07-31
EP2638042B1 (en) 2014-09-24
NO2023040I1 (no) 2023-10-20
SG190137A1 (en) 2013-07-31
NZ610468A (en) 2015-06-26
NI201300043A (es) 2013-07-01
PL2821407T3 (pl) 2017-04-28
ECSP13012676A (es) 2013-08-30
PT2638042E (pt) 2014-12-09
CO6801723A2 (es) 2013-11-29
AU2011326454A1 (en) 2013-05-23
TW201305165A (zh) 2013-02-01
BR112013011448B1 (pt) 2021-06-01
CN103328478B (zh) 2015-10-07
SG10201509335VA (en) 2015-12-30
HUE031010T2 (hu) 2017-06-28
MY165113A (en) 2018-02-28
EA201390683A1 (ru) 2013-09-30
IL225978A (en) 2015-11-30
ES2525021T3 (es) 2014-12-16
CA2817100A1 (en) 2012-05-18
SI2638042T1 (sl) 2015-01-30
US9833448B2 (en) 2017-12-05
DK2821407T3 (da) 2017-01-02
PE20140240A1 (es) 2014-03-14
RS53610B1 (en) 2015-04-30
KR20130087037A (ko) 2013-08-05
US20190275024A1 (en) 2019-09-12
US20120122899A1 (en) 2012-05-17
CN103328478A (zh) 2013-09-25
ES2604827T3 (es) 2017-03-09
US20180092900A1 (en) 2018-04-05
IL225978A0 (en) 2013-06-27
CY2023022I1 (el) 2024-02-16
BR112013011448A2 (pt) 2016-08-09
FIC20230034I1 (fi) 2023-11-10
US8754096B2 (en) 2014-06-17
US9499545B2 (en) 2016-11-22
WO2012064910A1 (en) 2012-05-18
JP2013542260A (ja) 2013-11-21
EP2638042A1 (en) 2013-09-18
GT201300122A (es) 2015-06-02
TWI522355B (zh) 2016-02-21
US20120122911A1 (en) 2012-05-17
US20120122900A1 (en) 2012-05-17
EP2821407A1 (en) 2015-01-07
US8481556B2 (en) 2013-07-09
US20150005330A1 (en) 2015-01-01
US8912210B2 (en) 2014-12-16
DK2638042T3 (en) 2015-01-05
US20170027925A1 (en) 2017-02-02
US20210008055A1 (en) 2021-01-14
ME02552B (me) 2017-02-20

Similar Documents

Publication Publication Date Title
FR23C1039I1 (fr) Derives de piperidinone carboxamide azaindane en tant qu'antagonistes du recepteur cgrp
FR22C1044I1 (fr) Antagonistes du recepteur cgrp
FR23C1031I1 (fr) Derives de lactames en tant qu'inhibiteurs d'idh1 mutants
FR2951172B1 (fr) Derives pyrazolopyridines en tant qu'agent anticancereux
ZA201504974B (en) Indole carboxamide derivatives as p2x7 receptor antagonists
SMT201600078B (it) Antagonista del recettore per cgrp
BR112012003263A2 (pt) formulações intravenosas de antagonistas de neuroquinina-1
DK3312169T3 (da) 5-ht3 receptorantagonister
DK3170501T3 (da) Antagonister af cb1-receptor
RS57232B1 (sr) Jedinjenja koja imaju muskarinske receptore aktivnosti antagonista i beta2 adrenergik receptore aktivnosti agonista
EP2637656A4 (en) PIPERIDINONE CARBOXAMIDE INDANES, CGRP RECEPTOR ANTAGONISTS
EP2685826A4 (en) PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN, CGRP RECEPTOR ANTAGONISTS
EP2654423A4 (en) AZAINDANE ANTAGONISTS HETEROCYCLIC CARBOXAMIDES MERGED FROM CGRP RECEPTORS
HK1203932A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists p2x7
SMT201500296B (it) Antagonisti del recettore trpm8
ZA201405959B (en) Novel neurokinin 1 receptor antagonist compounds
EP2654421A4 (en) CONDENSED HETEROCYCLIC INDAN CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS
DK2603206T3 (da) Farmaceutiske sammensætninger af metabotrofisk glutamat 5 receptor (mglu5)-antagonister
EP2686324A4 (en) Piperidinecarboxamide spirohydantoin-CGRP receptor antagonists
BR112015005750A2 (pt) antagonistas peptídicos do receptor de vasopressina-2
EP2846800A4 (en) HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
HK1183862A1 (en) Piperidinone carboxamide azaindane cgrp receptor antagonists (azaindane)(cgrp)
CO6990740A2 (es) Nuevo uso terapéutico de antagonistas de receptor p75